Compare CubeSmart (CUBE) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CubeSmart vs Sanofi SA — how do they compare? CubeSmart trades at $37.93 (market cap $8.45B), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 11.3× CubeSmart's market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold CubeSmart for 89 Days and Sanofi SA for 94 Days on average.
| CUBE | SNY | |
|---|---|---|
Market Cap | $8.45B | $95.18B |
Volume | 2,879,532 | 2,995,646 |
Sector | Real Estate | Health |
52-Week High | $42.50 | $52.34 |
52-Week Low | $35.36 | $39.51 |
Typical Hold Time | 89 Days | 94 Days |
Enterprise Value | $11.97B | $114.48B |
Dividend Yield | 5.65% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CubeSmart (CUBE) trades at $37.97, up 1.99% on the day, with a bearish technical outlook as moving averages signal selling pressure. The company reported mixed Q2 2026 results, with an FFO miss but revenue beat, and maintains strong profitability with a 29.41% net income margin. Recent news highlights institutional accumulation, with firms like NewEdge Advisors and Deutsche Bank increasing stakes, while analyst consensus leans toward Hold with a $44.00 price target.
The stock offers a 5.4% dividend yield and trades below the consensus target, suggesting potential upside if operational improvements materialize. Risks include high leverage with $2.99B in long-term debt and sensitivity to real estate market cycles. Earnings growth in H2 2026 is critical for reversing the current bearish sentiment.
Sanofi (SNY) trades at $40.07, down 0.32% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.21 exceeding the $1.10 estimate. Revenue for 2025 reached $46.72 billion, with a net income margin of 16.72%. Recent news highlights a significant $8 billion immunology alliance expansion with Regeneron, signaling strategic growth initiatives.
The outlook is mixed; solid profitability and a strategic partnership provide upside potential, but a projected net income decline to $4.0 billion in 2026 and bearish technical indicators pose risks. Analyst sentiment is cautiously optimistic with a 44% buy rating, though investors should monitor execution of new collaborations and patent expiration impacts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CubeSmart
CubeSmart is a real estate investment trust that acquires, owns, and manages self-storage facilities throughout the United States. The company's real estate portfolio is composed of buildings with numerous enclosed storage areas for both residential and commercial customers to rent mainly on a month-by-month basis. Most of CubeSmart's facilities are located in Florida, Texas, California, New York, and Illinois. Cumulatively, these states account for both the majority of the square footage in the company's real estate portfolio and the majority of its revenue. CubeSmart derives nearly all of its revenue from rental income from tenants utilizing its storage facilities.
Read more on CUBE →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
